Clinical Trial Update: Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density [Phase 2]

View source ↗

Summary

Phase 2 trial results assessing the efficacy, safety and tolerability of denosumab (AMG 162) in postmenopausal women with low bone mineral density.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

Sponsor: Amgen | Conditions: Low Bone Mineral Density | Phase 2 | Status: COMPLETED | Results posted: 2010-07-28